Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01051960 · ClinicalTrials.gov registry record · Phase 4
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
A Phase 4 study of Pulmonary Hypertension and Systemic Sclerosis, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01051960 is a Phase 4 study of Pulmonary Hypertension and Systemic Sclerosis that has completed, run by University of California, Los Angeles. The registered enrollment target is 12 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01051960, a Phase 4 study of Pulmonary Hypertension and Systemic Sclerosis, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis. The study also aims to determine the effectiveness of Ambrisentan for subjects with exercise induced Pulmonary Arterial Hypertension (PAH) with scleroderma
Conditions Studied
Interventions
- DRUG Ambrisentan
Study Locations (1)
California
- David Geffen School of Medicine, University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01051960
The ClinicalTrials.gov registry entry for NCT01051960 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (98% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Ambrisentan is the first listed.
NCT01051960 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01051960 about?
NCT01051960 is a clinical study titled "Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan". The purpose of this study is to determine the clinical characteristics and hemodynamic profiles that predict exercise induced pulmonary hypertension in 15 patients with systemic sclerosis. The study also aims to determine the effectiveness of Ambrisentan for subjects with exercise induced Pulmonary ...
What is the current status of trial NCT01051960?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2009-03. Estimated completion is 2011-01.
What conditions does trial NCT01051960 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Systemic Sclerosis, Shortness of Breath.
What interventions are being tested in trial NCT01051960?
The interventions under investigation include: Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT01051960?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01051960 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
ACTIVE NOT RECRUITING · Phase 4
-
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
COMPLETED · Phase 4
-
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
COMPLETED · Phase 4
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.